中国生物制药(01177.HK)：MSCI ESG评级升至AA级

Core Viewpoint - China Biopharmaceutical (01177.HK) has achieved an upgrade in its MSCI ESG rating from A to AA, establishing itself as a leader in ESG practices among global large pharmaceutical companies [1][4] Group 1: ESG Governance - The company has developed and continuously improved its ESG governance system, with the board as the highest decision-making body and "CARE" as the core ESG strategy, focusing on Cure, Accessible, Relationship, and Environmental [1] - The company integrates sustainable development concepts into corporate decision-making and business operations [1] Group 2: Environmental Initiatives - The company actively responds to the national "30·60" dual carbon goals, embedding green development concepts into its operations [2] - It has been a pioneer in the pharmaceutical industry by announcing carbon neutrality goals and has achieved over 10% annual reduction in major pollutant emissions for the past five years [2] - The company aims to synchronize the reduction of carbon emission intensity and total emissions by 2025, marking significant progress towards its carbon peak milestone [2] - Three of its subsidiaries have been recognized as national "green factories" [2] Group 3: Social Responsibility - The company adheres to the operational philosophy of "Health Technology, Warming More Lives," focusing on international innovation strategies to upgrade its business and fill clinical gaps [3] - It has invested over RMB 13 billion in R&D over the past three years and has established an international R&D platform [3] - The company has made strategic acquisitions to expand its innovation pipeline and technical platforms, including the full acquisition of Lixin Pharmaceutical Technology and Hejiya Biopharmaceutical [3] - It has served over 160 million patients with its key products in the past three years [3] - The company emphasizes talent development through employee care programs and training initiatives [3] - It has donated over RMB 150 million in the past three years to support disaster relief, rural revitalization, and inclusive healthcare [3] Group 4: Future Outlook - The upgrade to AA rating signifies high recognition of the company's ESG management and practices, marking a milestone in its commitment to sustainable development and corporate social responsibility [4] - The company aims to continue deepening its practices across environmental, social, and governance dimensions while leading the industry towards collaborative development [4] - It seeks to promote green and high-quality development in China's pharmaceutical health industry, creating sustainable shared value for stakeholders [4]